World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc. (AMEX:ISR), announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

“The patient tolerated the procedure well and had no evidence of cancer recurrence or any side effects that can be attributed to the Cesium-131 seed implant at the last follow-up visit.”

This implant was performed on a 38-year-old patient with locally recurrent colon cancer who underwent surgical resection of the tumor as a part of the treatment. The patient has a history of multiple prior surgeries and chemotherapy for colorectal cancer.

Dr. Parashar stated, “The patient tolerated the procedure well and had no evidence of cancer recurrence or any side effects that can be attributed to the Cesium-131 seed implant at the last follow-up visit.”

Cesium-131 was chosen for its short half-life and higher dose rate. In addition, the Cs-131 seed brachytherapy procedure has the advantage of relative safety to the medical staff (because of faster radioactive dose fall-off) if the patient requires additional medical care soon after the implant.

Cesium-131 is now being used successfully to treat lung, head and neck, ocular melanoma, and prostate cancers in other patients. In doing so, Cs-131 is expanding brachytherapy options for patients beyond the prostate to locally recurrent cancers in many areas of the body.

Dwight Babcock, IsoRay's CEO, stated, “In 2009, we made significant advancements in our strategy to provide Cesium-131 brachytherapy treatment to physicians to use in their arsenal of tools for fighting cancers throughout the body. We continue to build on that strategy in early 2010 by opening a lung study and moving forward with our preparations to expand the use of Cs-131 to additional areas in the body. We believe brachytherapy using Cs-131 has a unique and growing application to many areas within the body - not just the prostate.”

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning identifies cancer-driving mutations at CTCF binding sites